Palatin to Begin Trading on Nasdaq Stock Exchange

Rhea-AI Summary

Palatin (NYSE American: PTN) received approval to list its common stock on the Nasdaq Capital Market, with trading expected to begin on May 29, 2026 under the symbol PTN. Shares will trade on NYSE American until market close on May 28, 2026.

Palatin is advancing selective MC4R-based obesity programs, including a once-weekly injectable peptide agonist targeting an IND filing in Q4 2026 and an oral MC4R agonist with a next-generation candidate targeted for IND submission in the first half of 2027.

AI-generated analysis. Not financial advice.

Positive

• Nasdaq Capital Market listing approved, trading expected to begin May 29, 2026
• Ticker symbol PTN maintained through exchange transfer, avoiding investor confusion
• Once-weekly injectable MC4R agonist program targeted for IND submission in Q4 2026
• Next-generation oral MC4R agonist targeted for IND submission in first half 2027

Negative

• None.

News Market Reaction – PTN

-4.23%

1 alert

-4.23% News Effect

-8.5% Trough Tracked

-$1M Valuation Impact

$27.29M Market Cap

0.5x Rel. Volume

On the day this news was published, PTN declined 4.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $27.29M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Nasdaq start date: May 29, 2026 NYSE American end date: May 28, 2026 Injectable IND timing: Q4 2026 +1 more

4 metrics

Nasdaq start date May 29, 2026 Expected first trading day on Nasdaq Capital Market

NYSE American end date May 28, 2026 Last trading day on NYSE American

Injectable IND timing Q4 2026 Once-weekly injectable MC4R selective peptide agonist IND submission target

Oral IND timing H1 2027 Next-generation oral MC4R selective agonist IND submission target

Market Reality Check

Price: $14.12 Vol: Volume 23,011 is 1.51x th...

high vol

$14.12 Last Close

Volume Volume 23,011 is 1.51x the 20-day average of 15,284 ahead of the Nasdaq move. high

Technical Price 14.41 is trading above the 200-day MA at 12.33, 53.52% below the 31.00 52-week high and 16539.72% above the 0.0866 52-week low.

Historical Context

2 past events · Latest: May 13 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
May 13	Earnings and pipeline	Positive	-16.0%	Q3 2026 results, MC4R obesity program progress, and cash runway update.
Feb 17	Earnings and financing	Positive	+1.1%	Q2 2026 results, $18.2M offering, strengthened cash and MC4R plans.

Pattern Detected

Recent earnings have produced mixed reactions: one sharp selloff and one modest gain, suggesting news-driven volatility rather than a consistent directional pattern.

Recent Company History

Over recent quarters, Palatin reported earnings updates highlighting its MC4R-based rare obesity programs and improving loss profile. Q3 2026 showed $3.9M collaboration revenue and a narrower $1.4M net loss, while Q2 2026 included an $18.2M public offering that extended cash runway beyond Mar 31, 2027. Market reactions have been uneven, with a -16.01% move on the latest earnings and a smaller 1.15% gain previously. Today’s Nasdaq listing news follows this backdrop of balance-sheet repair and pipeline advancement.

Market Pulse Summary

This announcement details Palatin’s approved transfer from NYSE American to the Nasdaq Capital Marke...

Analysis

This announcement details Palatin’s approved transfer from NYSE American to the Nasdaq Capital Market on May 29, 2026, alongside timelines for IND submissions in Q4 2026 and H1 2027 for its MC4R obesity programs. Recent history includes a reverse split and prior delisting actions, as well as earnings reports showing collaboration revenue and extended cash runway. Investors may track execution on these clinical milestones and any further regulatory or financing disclosures as key indicators of progress.

Key Terms

nasdaq capital market, nyse american, melanocortin receptor system, mc4r, +4 more

8 terms

nasdaq capital market financial

"its common stock has been approved for listing on the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

nyse american financial

"transfer its stock exchange listing to Nasdaq from the NYSE American."

NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.

melanocortin receptor system medical

"development of novel therapeutics targeting the melanocortin receptor system"

A group of proteins on cell surfaces that act like locks receiving chemical keys to control body processes such as appetite, inflammation, skin pigmentation and energy use. Investors care because drugs that target these receptors can change how those systems work, creating new treatments or markets; progress in research, clinical trials or approvals can therefore drive a company’s value, while failures or safety concerns can harm it.

mc4r medical

"advancing selective MC4R-based obesity programs targeting rare obesity disorders"

mc4r is a gene that makes a protein in the brain acting like a thermostat for appetite and energy use; when it works normally it helps signal when to eat and when to stop. It matters to investors because changes in this gene or drugs that target its protein can alter obesity and metabolic disease outcomes, influencing clinical trial results, regulatory approvals, and the commercial prospects of therapies.

prader-willi syndrome medical

"including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

bardet-biedl syndrome medical

"including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome"

A rare inherited disorder caused by mutations in genes that act like a blueprint for the body, leading to a constellation of problems such as progressive vision loss, kidney dysfunction, obesity, extra fingers or toes, and developmental delays. Investors track it because treating or diagnosing the condition can create focused markets for drugs, genetic tests, medical devices, and long-term care services, and because clinical trial outcomes and regulatory decisions for therapies can materially affect company value.

ind submission regulatory

"program is on track for an IND submission in the fourth quarter of calendar 2026"

An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.

forward-looking statements regulatory

"Palatin products in development, clinical trial results, potential actions by regulatory agencies"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to trade on the NYSE American until the market close on May 28, 2026.

"We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."

Palatin is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a focus on improved tolerability and long-term use. The Company's once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of calendar 2026, and its oral MC4R selective agonist program continues to advance, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027. Palatin's development strategy is focused on advancing potential best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use.

No action is required by existing stockholders with respect to the transfer of the Company's listing.

About Palatin
Palatin is a biopharmaceutical company developing medicines that target the melanocortin receptor system with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form collaborations with industry leaders to maximize their commercial potential. For more information, visit the company's website at www.palatin.com and follow us on X, formerly Twitter, @PalatinTech.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the commencement of trading of Palatin's common stock on the Nasdaq Capital Market. Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

Palatin Technologies^® is a registered trademark of Palatin Technologies, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-begin-trading-on-nasdaq-stock-exchange-302774038.html

SOURCE Palatin Technologies, Inc.

FAQ

When will Palatin (PTN) begin trading on the Nasdaq Capital Market?

Palatin expects PTN to begin trading on the Nasdaq Capital Market on May 29, 2026. According to Palatin, its common stock will continue trading on NYSE American until the market close on May 28, 2026, ensuring a seamless exchange transfer for shareholders.

Will Palatin’s stock symbol change when PTN moves to Nasdaq in 2026?

Palatin’s stock symbol will remain PTN after the move to Nasdaq in 2026. According to Palatin, the company’s common stock will transfer from NYSE American to the Nasdaq Capital Market while continuing to trade under the same ticker, helping avoid symbol-related investor confusion.

What does the Nasdaq listing mean for Palatin (PTN) shareholders?

The Nasdaq listing is expected to increase visibility and may enhance liquidity for PTN shareholders. According to Palatin, management believes joining Nasdaq’s biotechnology community could improve exposure to institutional investors, although trading volume and valuation outcomes will still depend on broader market conditions and company execution.

What obesity programs is Palatin (PTN) advancing with its MC4R platform?

Palatin is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway. According to Palatin, these include hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with candidates designed to improve tolerability, reduce off-target effects, and support long-term use.

When are Palatin’s planned IND submissions for its MC4R obesity candidates?

Palatin targets an IND submission for its once-weekly injectable MC4R peptide agonist in Q4 2026. According to Palatin, its next-generation oral MC4R agonist candidate is targeted for IND submission in the first half of 2027, supporting a staged clinical development roadmap.

Does Palatin’s move to Nasdaq (PTN) require any action from existing shareholders?

Existing Palatin shareholders are not required to take any action for the Nasdaq listing transfer. According to Palatin, the company’s common stock will automatically transition from NYSE American to the Nasdaq Capital Market, with holdings and the PTN ticker remaining unchanged for investors.